Agreements

* On November 20, 2013,  Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, has announced  it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine. This agreement is part of Vect-Horus’ strategy to leverage its technological platform by entering into research and product development agreements with pharmaceutical and biopharmaceutical companies to generate patentable new chemical entities (NCEs) based on its partner’s drug or imaging candidates.

Vect-Horus is specialized in the development of vector molecules that allow delivery of therapeutic and imaging molecules in different organs and cell types, in particular in the central nervous system (brain and spinal cord). Indeed, the brain vascular system, known as the blood brain barrier, considerably restricts the delivery of drugs and imaging agents from blood to nervous tissue.

Vect-Horus is a French biotechnology company focused on developing vector molecules and vectorized drug-candidates for drug delivery to the central nervous system and for the treatment of CNS diseases. Founded in 2005 by Alexandre Tokay and Michel Khrestchatisky, the company is a spin-off from the CNRS UMR7529 managed by Dr. Michel Khrestchatisky. Vect-Horus has 15 employees (most in R&D) and has secured EUR 9 million in equity and subsidies. It collaborates with CEA Saclay SIMOPRO managed by Dr. Vincent Dive and the INSERM unit U705 managed by Pr. Jean-Michel Scherrmann.